Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

By Oskar Hansson, Henrik Zetterberg, Peder Buchhave, E. Londos, Kaj Blennow, Lennart Minthon. Lancet Neurology, 2006

1,711 citations recorded by the source corpus.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/d3964c221b31bbb95d123e40dcd31bff1cfa3fc1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Kaj Blennow
2. Henrik Zetterberg
3. D. Holtzman
4. Oskar Hansson
5. John C. Morris
6. A. Goate
7. Philip Scheltens
8. Daniel Rueckert

In Physiology

1. D. Holtzman
2. Kaj Blennow
3. Henrik Zetterberg
4. A. Goate
5. Reisa A. Sperling
6. John C. Morris
7. Oskar Hansson
8. Michael D. Geschwind

In Psychiatry and Mental health

1. Kaj Blennow
2. D. Holtzman
3. Henrik Zetterberg
4. Oskar Hansson
5. Michael D. Geschwind
6. Michael G. Erkkinen
7. Mee‐Ohk Kim
8. John C. Morris

Citations in the corpus

• DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. (2010, neutral): “patients with Alzheimer’s disease (Hansson et al., 2006).”
• Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “The presence of CSF AD biomarkers in patients with mild cognitive impairment increases their risk of developing AD (Hansson et al. 2006).”
• Random forest-based similarity measures for multi-modal classification of Alzheimer's disease (2013, positive): “MCI patients tend to have CSF A β and tau levels between those expected of AD patients and healthy controls, with AD-like biomarker levels associated with an increased likelihood of progression to AD (Hansson et al., 2006).”
• Brain imaging in Alzheimer disease. (2012, background): “…in CSF Ab42 appear to occur early (at least as early as changes in amyloid PET) and precipitously— achieving its final level very early in the course of the pathophysiological spectrum of AD— probably presymptomatically (Blennow and Hampel 2003; Hansson et al. 2006; Fagan et al. 2007, 2009).”
• Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease (2009, neutral): “Inferences about the relationship between CSF AB 1–42 and longitudinal disease progression have been mixed (Clark et al ., 2003; Wahlund and Blennow, 2003; Hampel et al ., 2004; de Leon et al ., 2006; Hansson et al ., 2006; Engelborghs et al ., 2007; Fagan et al ., 2007; Sluimer et al ., 2008).”
• Cerebrospinal Fluid Biomarker Signature in Alzheimer’s Disease Neuroimaging Initiative Subjects (2009, result): “Ann Neurol 2009;65:403–413 If the clinical diagnosis of probable AD is imprecise with accuracy rates of approximately 90% or lower using established consensus criteria for probable AD, but definite AD requires autopsy confirmation, it is not surprising that diagnostic accuracy is lower at early and ”
• Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease (2010, background): “In addition to cerebrospinal fl uid derived biomarkers (Blennow and Hampel, 2003; Ewers et al., 2007; Hansson et al., 2006; Herukka et al., 2007; Zhong et al., 2007), neuroimaging markers have been recommended to be included in the revised NINCDS-ADRDA diagnostic…”